Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

153.25 -12.59 (-7.59%)
Official Closing Price Updated: 7:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Warren Buffett's Granddaughter Claimed He Cut Her Off And She Couldn't Afford Health Insurance: 'He Disowned My Twin Sister And Myself'
Via Benzinga
2 Stocks to Buy if There Is a Market Crash in 2025
Via The Motley Fool
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years
On Friday, Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz). 
Via Benzinga
(JNJ) - Analyzing Johnson & Johnson's Short Interest
Via Benzinga
Kenvue's Q4 Sales Miss, Margins Improve
Kenvue posted mixed Q4 earnings, with in-line EPS but revenue below estimates, driven by challenges in its Skin Health and Beauty segment. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Is Johnson & Johnson Stock a Buy?
Via The Motley Fool
Johnson & Johnson's Options Frenzy: What You Need to Know
Via Benzinga
Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q4 Results Tomorrow
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results tomorrow before the bell. Here’s what you need to know. 
Via StockStory
What To Expect From Eli Lilly’s (LLY) Q4 Earnings
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow morning. Here’s what to expect. 
Via StockStory
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference
From Johnson & Johnson
Via Business Wire
Can Biotech Stocks Survive The Precarious Macro?
We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows. 
Via Talk Markets
Topics Stocks / Equities World Trade
Exposures Tariff
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
Teva Pharmaceuticals is the world's largest generic drug maker with over 500 generics in its portfolio, but shares sold off on its recent earnings, buying opp? 
Via MarketBeat
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?
Via The Motley Fool
Did Johnson & Johnson Just Give Investors 23 Billion Reasons to Buy Its Stock?
Via The Motley Fool
The Dogs Of The Dow 2025
The Dogs of the Dow is an investing strategy well-known to retail and institutional investors. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Johnson & Johnson (NYSE:JNJ) Posts Q4 Sales In Line With Estimates
Multinational healthcare company Johnson & Johnson (NYSE:JNJ) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 5.3% year on year to $22.52 billion. Its non-GAAP profit of $2.04 per... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people. 
Via Benzinga
Topics Government
Exposures Political
Starbucks To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Marjorie Taylor Greene Loads Up On Meta, Amazon, Tesla, Nvidia And Other Stocks As Donald Trump's New Equations With Big Tech Leaders Sets Stage For Growth: What Is At Stake?
U.S. House Representative Marjorie Taylor Greene has disclosed new trades as Donald Trump's equations evolves with Big Tech leaders. 
Via Benzinga
Topics Government
Exposures Political
Georgia Rep. Marjorie Taylor Greene Bought Up to $45K Worth of Johnson & Johnson Stock
Via Benzinga
3 Stocks Upgraded by Bank of America – Here's Why They're Bullish
Bank of America analysts have recently shifted their views on these three stocks, leaving investors with a few points to consider. 
Via MarketBeat
McDonald's To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Traders Are Buying the Dip on Johnson & Johnson Stock
Shares of Johnson & Johnson stock have declined by 11.5% in the quarter, and markets are calling for a bottom and rally here. 
Via MarketBeat
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
Via The Motley Fool
Topics Stocks
Exposures US Equities
Abbott Laboratories Will Outperform Healthcare Stocks in 2025
Johnson & Johnson and Abbott Laboratories offer substantial opportunities for investors, but one is a better buy for total returns in 2025 and 2026. 
Via MarketBeat
5 of the Safest High-Yield Dividend Stocks You Can Confidently Buy for 2025
Five magnificent income stocks -- sporting an average yield of 4.26% -- can pad investors' pocketbooks in the new year (and well beyond). 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.